Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock

Organogenesis (NASDAQ:ORGO) Director Arthur Leibowitz purchased 5,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average cost of $2.68 per share, for a total transaction of $13,400.00. Following the transaction, the director directly owned 291,014 shares in the company, valued at approximately $779,917.52. This represents a 1.75% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Organogenesis Stock Performance

Shares of Organogenesis stock opened at $2.68 on Thursday. The company has a current ratio of 3.62, a quick ratio of 3.32 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average price is $3.79 and its 200-day moving average price is $4.48. The firm has a market cap of $344.76 million, a P/E ratio of 33.50 and a beta of 1.43. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The company had revenue of $225.61 million during the quarter, compared to analyst estimates of $172.68 million. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. On average, equities research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

A number of institutional investors have recently modified their holdings of the company. Strs Ohio purchased a new position in shares of Organogenesis in the 1st quarter worth approximately $105,000. Acadian Asset Management LLC lifted its position in Organogenesis by 3.9% during the second quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock valued at $8,862,000 after acquiring an additional 91,118 shares during the last quarter. Creative Planning boosted its stake in Organogenesis by 84.5% in the second quarter. Creative Planning now owns 35,392 shares of the company’s stock valued at $130,000 after acquiring an additional 16,205 shares in the last quarter. Cetera Investment Advisers acquired a new stake in Organogenesis in the second quarter valued at approximately $222,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Organogenesis in the second quarter worth $63,000. 49.57% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ORGO shares. BTIG Research dropped their price objective on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Weiss Ratings upgraded Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, February 27th. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a research report on Sunday. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.